Sanofi Joins CMAC as Tier 1 Partner, Fostering Research & Innovation in Advanced Pharmaceutical Development & Manufacturing
CMAC is delighted to announce its new partnership with Sanofi, a leading global pharmaceutical company, as a Tier 1 member. This collaboration marks a significant milestone for the Centre in driving collaborative research and innovation within advanced pharmaceutical manufacturing.
Sanofi joins a consortium of eight Tier 1 partners within the global pharmaceutical industry alongside AstraZeneca, Chiesi, Eli Lilly, Pfizer, Roche, Takeda and UCB. As a Tier 1 partner, Sanofi gains access to unparalleled resources, including world-class facilities, peer-to-peer knowledge exchange, PhD placements, technical translation pathways, mentorship opportunities, and the ability to shape pioneering research programmes.
Sanofi's expertise will further strengthen CMAC's research portfolio, particularly in accelerating the implementation of CMAC Strategy and our main research and translation to industry streams (i.e. CCSᵃ, MCS+ᵇ, BPCSᶜ and Quality by Digital Design, QbDD). Their dedication to Digital Transformation of CMC (Chemistry, Manufacturing and Control) seamlessly aligns with CMAC's vision to revolutionise medicines manufacturing, fostering a sustainable and impactful approach.
Massimo Bresciani, CMAC Industry Director, stated: “We are thrilled to welcome Sanofi to our esteemed roster of Tier 1 partners at CMAC. This exciting collaboration underpins our mutual dedication to innovation, propelling us towards a future where collective expertise drives significant industry breakthroughs.”
Robert Yule, Head of US Engineering and Modelling at Sanofi, said: “Sanofi looks forward with working with CMAC to advance the use of Digital Twins and promote continuous manufacturing with the goal of producing lower cost drugs that have more eco-friendly manufacturing processes.”
About CMAC
CMAC is an internationally leading medicines manufacturing research centre with a unique configuration of academic research, applied, and pre-competitive programs. Working in partnership with Tier 1, Tier 2, academic, and innovation partners, CMAC's goal is to transform Medicines Development, Manufacture & Supply, and further grow its pipeline of world-class multi-disciplinary collaborative research. The centre’s portfolio currently includes the Made Smarter Innovation: Digital Medicines Manufacturing Research Centre (DM²), EPSRC international Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) collaboration, UKRPIF supported Net Zero Pilot and CMAC Data Lab, and the EPSRC CMAC Future Manufacturing Research Hub, along with training and translation projects within a world-class facility.
For more information on CMAC visit: https://cmac.ac.uk/
About Sanofi:
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
For more information on Sanofi, visit: https://www.sanofi.com/en
Learn more about CMAC’s partners: https://cmac.ac.uk/our-partners
Acronyms
ᵃ Crystallisation Classification System, CCS
ᵇ Digital Manufacturing Classification System, MCS+
ᶜ Biorelevant Performance Classification System, BPCS